Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States

Completed

Conditions studied: Hiv, HIV-1-infection, HIV Infections

In brief

This real-world retrospective study describes the clinical efficacy of 2DR (DOVATO® (DTG/3TC)) versus 3DR (BIKTARVY® (BIC/F/TAF)) in PWH, including those with at least 2 social determinants of health indicators, across a multi clinic infectious disease organization in the Southeast United States

Key facts

Study ID

NCT06393387

Run by

Midway Specialty Care Center

People needed

800

Starts

2024-06-01

Expected to finish

2025-04-01

Last updated by the study team

2025-09-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults, aged 18 years and older;
• Diagnosis of HIV-1;
• Have a history of ART consisting of DTG/3TC or BIC/F/TAF, initiated from May 1, 2019 through January 28, 2023;
• Have at least 48 weeks of clinical follow up after initiation of DTG/3TC or BIC/F/TAF; clinical follow-up can include time post-discontinuation of either index regimen;
• Complete data, for HIV-1 RNA viral load at all study time points, including baseline, through 24 weeks and through 48 weeks;
• Received care from a physician, nurse practitioner or physician assistant at the organization

You may not qualify if…

• Index regimen is BIC/F/TAF and has a history of ART consisting of DTG+3TC or DTG/3TC;
• Index regimen is DTG/3TC and has a history of ART consisting of BIC/F/TAF

Where it is running

• Midway Specialty Care Center — West Palm Beach, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.